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Inﬁltration and local proliferation are known factors that contribute to tubulointerstitial macrophage accumulation. This study
explored the time course of these two contributors’ roles as tubulointerstitial inﬂammation and ﬁbrosis progressing, and evaluated
the mechanisms of the protective eﬀect of atorvastatin. Unilateral ureteral obstructive (UUO) rats were treated with atorvastatin
(10mg/Kg) or vehicle. Expression of osteopontin (OPN) and macrophage colony-stimulating factor (M-CSF) was evaluated by
RT-PCR and immunohistochemistry. Immunohistochemistry staining of ED1 was used to assess macrophage accumulation in
interstitium. Histological evaluation was performed to semiquantify tubulointerstitial ﬁbrosis. The results showed that on day 3
after UUO operation, OPN expression signiﬁcantly increased and positively correlated with the number of the interstitial ED1+
cells, while on day 10, M-CSF expression upregulated and correlated with interstitial ED1+ cells. In atorvastatin treatment group,
the increments of these two factors were attenuated signiﬁcantly at the two time points, respectively. ED1+ cell accumulation and
ﬁbrosis also ameliorated in the treatment group. For all the samples of UUO and treatment group on day 10, ED1+ cells also cor-
related with interstitial ﬁbrosis scores. The results suggest that OPN may induce the early macrophage/monocyte inﬁltration and
M-CSF may play an important role in regulating macrophage accumulation in later stage of UUO nephropathy. Statin treatment
decreases interstitial inﬂammation and ﬁbrosis, and this renoprotective eﬀect may be mediated by downregulating the expression
of OPN and M-CSF.
Copyright © 2006 Shaojiang Tian et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
The chronic inﬂammation characterized by macrophage ac-
cumulation in glomeruli and the interstitium is a com-
mon feature in most types of glomerulonephritis. Tubuloin-
terstitial macrophage accumulation in particular correlates
with kidney disease progression [1]. Indeed, studies have
shown that interstitial macrophage accumulation is predic-
tive of disease progression in severe forms of human and
experimental glomerulonephritis [2–4]. The accumulated
macrophage may directly or indirectly be involved in tubu-
lointerstitial ﬁbrosis [5], which is the hallmark of irreversible
chronic kidney injury. So, the study investigating the mecha-
nisms of macrophage accumulation may shed a light on pre-
vention of chronic kidney disease.
Studies have shown that interstitial macrophage accu-
mulation is due to the results of monocyte/macrophage
(M/M) inﬁltration and local proliferation [6]. Recent study
has revealed that osteopontin (OPN) plays an important
role in chemotaxis on M/M inﬁltration in a rat model of
anti-GBM glomerulonephritis [7], and macrophage colony-
stimulating factor (M-CSF) is a critical factor that induces
strong local macrophage proliferation [8, 9]. Although the
function of these two cytokines has been identiﬁed, which
one at which time plays a predominant role remains un-
clear. Ophascharoensuk et al reported that macrophage in-
ﬂux was less in OPN−/− mice compared to OPN+/+m i c e
in early stage (day 4 and day 7) in unilateral ureteral obstruc-
tive (UUO) nephropathy, but not in later stage (day 14) [10].
LeMeuretalhavealsofoundthatfollowingUUO,kidneyM-
CSF mRNA increased in association with local macrophage
proliferation in later stage (days 5 and 10). Anti-c-fms (an-
tibody to receptor of M-CSF) treatment caused a minor
inhibition of monocyte recruitment at day 1, but reduced
macrophage accumulation by 75% at day 10 [11]. Those
studies implicate that diﬀerent cytokines may be responsible2 Mediators of Inﬂammation
for the macrophage accumulation in diﬀerent phases. How-
ever, the study investigating the time course of these two cy-
tokines’expressioninasamegroupofpatients/animalsisstill
lacking, so we cannot get an integral interpretation about the
time order of these two contributors’ roles.
Chronic unilateral ureteral obstruction is a well-charac-
terized experimental model of renal injury leading to tubu-
lointerstitial inﬂammation and ﬁbrosis [12]. This is because
it is normotensive, nonproteinuric, nonhyperlipidemic, and
without any apparent immune or toxic renal insult. Studies
have shown the prominent M/M accumulation in UUO kid-
ney, so we chose UUO rat as our interstitial inﬂammation
and ﬁbrosis model. Meanwhile, recent studies have revealed
that statin can suppress the accumulation of M/M in this ex-
perimental kidney disease [13, 14], so we testify the protec-
tive eﬀect of atorvastatin and try to investigate the mecha-
nisms of this eﬀect in UUO nephropathy.
MATERIALS AND METHOD
Animalsandreagents
Adult male Sprague-Dawley rats (180–220g) were obtained
from Experimental Animal Breeding Center of Medical Col-
lege of Wuhan University. Monoclonal antibodies used were
mouse anti-rat ED1 (Serotec Co), mouse anti-rat OPN (Na-
tional Health Research Institution, USA), and goat anti-rat
M-CSF (Santa Cruz Biotech). The primers for OPN, M-
CSF, and GAPDH were produced by TaKaRa Co. SPkit was
the production of Zymed Co. Atorvastatin was provided by
Pﬁzer Pharmaceutical Ltd.
Experimentaldesign
All the 42 rats were randomly divided into 3 groups as fol-
lows: (1) sham-operated group; (2) UUO; (3) UUO+ ator-
vastatin. The general procedure of rat UUO operation is the
sameaspreviouslydescribed[15].Aftergeneralanesthesiaby
muscular injection of ketaminum (60mg/kg body weight),
alltheanimalsunderwentleftproximalureteralligation.The
left ureter was identiﬁed through a suprapubic incision and
was ligated with 4.0 silk at two points, and then cut between
the two points. Sham operation was done without ureteral
ligation and cut. The left kidneys were harvested from the
a n i m a l sa td a y3o r1 0a f t e ru r e t e r a lo b s t r u c t i o no p e r a t i o n .
At each time point, 7 rats were sacriﬁced in each group.
In UUO+ atorvastatin group, rats were orally adminis-
teredatorvastatin(10mg/kgbodyweightperday)fromthree
days before the UUO operation to the day of sacriﬁce. For
all animals, before removing the kidney, blood samples were
obtained from heart, and then centrifuged at 3000rpm and
serum was stored at −70◦C for later use.
Morphology
Renal tissue at sacriﬁce was ﬁxed in 10% formalin and em-
bedded in paraﬃn. For evaluating tubular lesions, sections
were stained with PAS reagent. Tubular lesions, character-
ized by tubular dilation and epithelial desquamation with
interstitial expansions, were graded according to the extent
of cortical involvement on a scale from 0 to 4 [16]: 0 =
normal; 1 = involvement of less than 25% of the cortex;
2 = involvement up to 25% to 50% of the cortex; 3 =
involvement up to 50% to 75% of the cortex; 4 = extensive
damage involving more than 75% of the cortex. Then they
were expressed as tubular injury scores. An observer blinded
to the origin of the sections, examined tubulointerstitial
ﬁelds adjacent to an arbitrary glomerulus at ×200. Sections
werealsostainedwithMassontrichromeidentifyingcollagen
ﬁbers (in blue). Histological assessment of collagen deposi-
tion was determined by the point-counting method using a
10×10grid[17].Aminimumof10highpower(×400)ﬁelds
were assessed per animal and results expressed as % total in-
terstital cortical area, excluding glomeruli, blood vessels, and
periglomerular and perivascular areas.
Immunohistochemistry
Sections of formalin-ﬁxed, paraﬃn-embeded tissue were de-
waxed,rehydrated,microwaved,andstainedusingastandard
three-layer method as recommended by SP kit. When mea-
suring OPN, the ﬁrst antibody was mouse anti-rat OPN an-
tibody; when examining the M-CSF expression, the ﬁrst an-
tibodywasgoatanti-ratM-CSFantibody;andwhenmeasur-
ing macrophage accumulation, the ﬁrst antibody was mouse
anti-rat ED1 antibody. The bound peroxidase was developed
with diaminobenzidine to produce a brown colour followed
by a blue nuclear haematoxylin counterstain.
Quantitationofimmunohistochemistry
The OPN and M-CSF immunostaining was measured by
evaluating the labeling index in tubules of the kidney with a
computer-assisted image analyzer system (HPIAS-1000) and
expressed by integral optical density (IOD). The number of
interstitial ED1+ cells was counted in 100 consecutive high-
power (×400) ﬁelds and expressed as cells per HP.
Reversetranscriptase-polymerasechainreaction
Total RNA was extracted from kidney tissue using RNA-
zol BTM (Protech, Inc, USA) according to the manufac-
turer’s instructions. Reverse transcription of 1μgR N Aw a s
performed using 100pmol random OligA primers (Amer-
sham Pharmacia Biotech, Uppsala, Sweden) and 300U Su-
perScript RNAse H (GIBCO BRL) with the mixture of 5μl
buﬀer, 10μm o ld N T P ,0 . 1 m m o lD T T ,a n d6 0 UR N A s i n
(Boehringer Mannheim, Mannheim, Germany) at 42◦Cf o r
1h. PCR was performed using the following primers: OPN:
forward primer 5 -GAT GAG TCC TTC ACT GCC AGCA;
reverse primer 3 -CGA TAG CAT CCG ACC GCT CTG
(amplifying a 418bp fragment); M-CSF: sense-AGT GAG
GGA TTT TTG ACC CAG; antisense-AGA TGA ACC ATC
CGT CTT CTC (amplifying a 234bp fragment); GAPDH:
sense-ACC ATG GAG AAG GCT, antisense-AGT GTA GCC
CAG GAT (amplifying a 522bp fragment). PCR of 2μlo f
the cDNA was performed with 0.025U/μlT a qp o l y m e r a s e
(GIBCOBRL),2mMMgCl2,0.2mMdNTP,PCRbuﬀer,andShaojiang Tian et al 3
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Figure 1: ED1+ cell accumulation at diﬀerent time points in three groups (×400). Sections were stained using a standard three-layer
method as recommended by SP kit. Macrophage accumulation was measured by immunohistochemistry and quantiﬁed by the number
of ED1+ cells/HP: (a) sham group, (b) UUO on day 3, (c) UUO on day 10, (d) treatment group on day 3, and (e) treatment group on day
10. ∗∗: P<. 01 versus sham group of the same time point. ##: P<. 01 versus UUO group of the same time point.
0.5μM of each primer in a ﬁnal volume of 50μl in a DNA
thermocycler 480 (Perkin Elmer, Norwalk, Conn, USA). Af-
ter 3min at 94◦C, PCR was conducted for 30 cycles (pi-
lot studies were performed to ensure that the reaction was
within the linear phase) using the following conditions: 455
of denaturation at 94◦C, 1min of annealing at 55/57◦C, and
1min of extension at 72◦C, followed by a ﬁnal extension for
5minat72 ◦C and cooling to 4◦C.
The PCR products were separated by electrophoresis on
a1 .5% agarose gel (GIBCO BRL). Following staining with
ethidium bromide, the gels were photographed and digitized
by using a scanner (Lacie Silver Scanner for Macintosh) and
the DeskScan software (Adobe PhotoShop). The image was
inverted before performing densitometric analysis by using
NationalInstituesofHealthImage1.6software.Aratioofthe
intensity between OPN and GAPDH or M-CSF and GAPDH
was calculated.
Measurementofserumlipids
The serum lipid was tested in our hospital laboratory depart-
ment. The parameters include total cholesterol, total triglyc-
erol, and HDL-cholesterol.
Statisticalanalysis
Results are present as the mean ±SD. The number of macro-
phage, expression of OPN and M-CSF at diﬀerent time
points in three groups, was analyzed by one-way analysis of
variance(ANOVA)followedby q testusingtheSPSSforwin-
dows10.0.Inaddition,thecorrelationsbetweenmacrophage
accumulation and cytokines staining or ﬁbrosis index were
performed by the Spearman’s rank correlation coeﬃcient.
Statistical signiﬁcance was deﬁned as P<. 05.
RESULTS
Macrophageaccumulation
As illustrated in Figure 1,f e wm a c r o p h a g e sw e r eo b s e r v e di n
sham-operated rat kidney. There was a signiﬁcant increase
in the number of interstitial ED1+ cells on day 3 in UUO
group and more ED1+ accumulation on day 10. In UUO+
atorvastatin-treated group, interstitial ED1+ macrophage ac-
cumulation was markedly decreased on day 3 and day 10
when comparing with UUO animals at the same time points,
respectively.4 Mediators of Inﬂammation
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Figure 2: Tubular injury score at diﬀerent time points in three groups (×100). Sections were stained with PAS regent. Tubular lesions were
graded according to the extent of cortical damage: (a) sham group, (b) UUO on day 3, (c) UUO on day 10, (d) treatment group on day 3,
and (e) treatment group on day 10. ∗∗: P<. 01 versus sham group of the same time point. ##: P<. 01 versus UUO group of the same time
point.
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Figure 3: Tubulointerstitial ﬁbrosis at diﬀerent time points in three groups (×200). Sections were stained with Masson trichrom identifying
collagen ﬁbers. Collagen deposition was determined by the point-counting method: (a) sham group, (b) UUO on day 3, (c) UUO on day 10,
(d) treatment group on day 3, and (e) treatment group on day 10. ∗∗: P<. 01 versus sham group of the same time point. ##: P<. 01 versus
UUO group of the same time point.Shaojiang Tian et al 5
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Figure 4: Staining of OPN at diﬀerent time points in diﬀerent groups (×200). Using antibody against OPN, sections were stained by immuno-
histochemistry. Labeling index was expressed by integral optical density (IOD): (a) sham group, (b) UUO on day 3, (c) UUO on day 10, (d)
treatment group on day 3, and (e) treatment group on day 10. ∗∗: P<. 01 versus sham group of the same time point. ##: P<. 01 versus
UUO group of the same time point.
Tubulointerstitialinjuryandﬁbrosisandcorrelation
withED1+ cellaccumulation
Therewasmarkedtubulardamageonday3andmorepromi-
nently on day 10 after UUO operation, atorvastatin treat-
ment reduces tubular injury both on day 3 and on day 10
(as shown in Figure 2). To assess tubulointerstitial ﬁbrosis,
Masson trichrome staining was performed. The results indi-
cated signiﬁcantly higher ﬁbrosis score on day 10 in UUO
group. The atorvastatin treatment attenuated interstitial ﬁ-
brosis at that time point (as shown in Figure 3). For all sam-
ples of UUO and treated group on day 10, the number of
ED1+ interstitial cells signiﬁcantly correlated with the index
of interstitial ﬁbrosis detected by Masson trichrome staining
(r = 0.58, P<. 01).
OPNandM-CSFexpressionandcorrelation
withmacrophageaccumulation
The induction of UUO nephropathy led to signiﬁcantly in-
creasedtubularexpressionofOPNonday3,butthisincrease
attenuated signiﬁcantly on day 10. The expression of M-CSF
did not upregulate on day 3 but increased and reached sta-
tistical signiﬁcance on day 10. In atorvastatin-treated group,
the OPN expression on day 3 and the M-CSF expression
on day 10 were signiﬁcantly ameliorated, respectively, when
comparing with UUO group (results are shown in Figures 4
and 5). The reverse transcriptase-polymerase chain reaction
(RT-PCR) analysis indicated that the mRNA of OPN on day
3 in UUO group increased by about 13-fold comparing with
that of sham group, but decreased to about 9-fold on day
10 (as shown in Figure 6). The expression of M-CSF mRNA
was statistically identical to sham group on day 3 and dra-
matically increased by about 7-fold on day 10 in the UUO
group (data shown in Figure 7). When taking all the samples
of UUO and UUO+ atorvastatin group on day 3 for correla-
tion analysis, there was a signiﬁcant positive correlation be-
tween the ED1+ cells accumulation and the staining of OPN
(r = 0.71, P<. 01). When analyzing all samples of these two
groups on day 10, the ED1+ cell accumulation was positively
correlated with the staining of M-CSF (r = 0.82, P<. 01).
Serumlipid
Serum lipid level of all the 3 groups is shown in Table 1.A si t
demonstrated,therewasnosigniﬁcantdeviationonanytime
points among these groups.
DISCUSSION
The present study demonstrated that in early stage of UUO
nephropathy, OPN expression increased and correlated with6 Mediators of Inﬂammation
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Figure 5: Staining of M-CSF at diﬀerent time points in diﬀerent groups by immunohistochemistry (×200). Using antibody against M-CSF,
sections were stained by immunohistochemistry. Labeling index was expressed by integral optical density (IOD): (a) sham group, (b) UUO
on day 3, (c) UUO on day 10, (d) treatment group on day 3, and (e) treatment group on day 10. ∗∗: P<. 01 versus sham group of the same
time point. ##: P<. 01 versus UUO group of the same time point.
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Figure 6:ExpressionofOPNatdiﬀerenttimepointsindiﬀerentgroupsbyRT-PCR.TotalRNAwasextractedfromkidneytissueattheindicated
timeandreverse-transcribedtocDNA.cDNAwassubjecttoPCR,andOPNwasampliﬁedto418bpfragments.GAPDHwasusedasinternal
control (a) on day 3 in sham group, (b) on day 10 in sham group, (c) on day 3 in UUO group, (d) on day 10 in UUO group, (e) on day 3
in treatment group, and (f) on day 10 in treatment group. ∗∗: P<. 01 versus sham group of the same time point. ##: P<. 01 versus UUO
group of the same time point.Shaojiang Tian et al 7
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Figure 7: Expression of M-CSF at diﬀerent time points in diﬀerent groups by RT-PCR. Total RNA was extracted from kidney tissue at the
indicated time and reverse-transcribed to cDNA. cDNA was subject to PCR, and M-CSF was ampliﬁed to 234bp fragments. GAPDH was
used as internal control (a) on day 3 in sham group, (b) on day 10 in sham group, (c) on day 3 in UUO group, (d) on day 10 in UUO group;
(e) on day 3 in treatment group, and (f) on day 10 in treatment group. ∗∗: P<. 01 versus sham group of the same time point. ##: P<. 01
versus UUO group of the same time point.
Table 1: Serum lipid level at diﬀerent time points of diﬀerent groups.
Sham UUO Treated
Day 3 Day 10 Day 3 Day 10 Day 3 Day 10
T-ch (mmol/L) 1.53 ±0.21 1.64 ±0.78 1.57 ±0.49 1.48 ±0.36 1.62 ±0.59 1.54 ±0.28
T-G (mmol/L) 0.76 ±0.37 0.69 ±0.45 0.72 ±0.29 0.72 ±0.11 0.75 ±0.23 0.76 ±0.33
HDL-C (mmol/L) 1.11 ±0.35 1.06 ±0.52 1.16 ±0.49 1.20 ±0.66 1.19 ±0.32 1.09 ±0.41
interstitial macrophage accumulation, while in later stage,
M-CSF expression increased and correlated with interstitial
macrophage accumulation. Atorvastatin treatment amelio-
rated the increments of these two cytokines’ expression at
two time points, respectively, and also reduced the intersti-
tial macrophage accumulation and ﬁbrosis.
Numerous studies have investigated the role of OPN and
M-CSF in tubulointerstitial macrophage accumulation [7–
9, 18]. Using OPN knockout mice, Persy et al veriﬁed that
OPN was a critical factor for interstitial macrophage accu-
mulation [19]. Meanwhile, Lenda et al also conﬁrmed that
macrophage proliferation was reduced in M-CSF deﬁcient
mice [20]. On the contrary to the abundant studies in test-
ing those cytokines’ role, only few reports evaluated the time
course of these two factors’ roles. An integral and compre-
hensive explanation that temporally considered these two in-
ﬂammatorymediatorsisstilllacking.Thepresentstudyiden-
tiﬁed, to our knowledge for the ﬁrst time, the pattern of
these two cytokines’ expression in UUO nephropathy, and
provided strong evidence for our postulation that it is the
diﬀerent cytokines that play a predominant role at diﬀerent
timepointsinmacrophageaccumulationinUUOnephropa-
thy. Our ﬁndings make us reason that OPN and M-CSF are
sequentially expressed in tubular cells and regulated intersti-
tial macrophage accumulation in diﬀerent phases.
Our study also indicated that macrophage accumulation
correlated with interstitial ﬁbrosis. Although tubulointersti-
tial inﬂammation may not be the prerequisite of the onset
of interstitial ﬁbrosis [21], and ﬁbrosis cannot be reversed by
agents that suppress inﬂammatory cell activation alone [22],
taken together with other studies, our study support that
interstitial inﬂammation may be involved in and accelerate
this process. Recent study has also revealed that chemokine
receptor antagonist reduce interstitial inﬂammation and
ﬁbrosis [3, 23]. All those reports underline the recognition
that macrophage accumulation could be considered as a ma-
jor component involved in the tubulointerstitial ﬁbrosis.
Statins (HMG-CoA reductase inhibitor) have been
shown to inhibit macrophage accumulation in tubuloint-
erstitium independent of their cholesterol-lowering eﬀects
[24]. This study demonstrated that atorvastatin reduced the
number of macrophage on day 3 and on day 10 after UUO
operation through downregulating the expression of OPN
and M-CSF independent of cholesterol-lowering eﬀects. We
suppose that this may be the mechanistic insight that ex-
plains how atorvastatin exerts this anti-inﬂammation eﬀect.8 Mediators of Inﬂammation
Studies also have shown that atorvastatin downregulates the
expression of adhesion molecule in endothelial cells [25],
which is also related to macrophage accumulation. In UUO
nephropathy, atorvastatin reduces OPN expression which
may also be related to its inhibiting eﬀect on angiotensin II
[26], because studies have shown that angiotensin II is a po-
tent inducer of OPN [18]. On the other hand, atorvastatin
also can inhibit NF-kappa B activation [13]. This eﬀect may
be related to its role in downregulating M-CSF expression
[27]. But, all these presumptions need more studies to in-
vestigate because of the complicated interaction of these cy-
tokines in vivo.
In our study, atorvastatin signiﬁcantly reduced intersti-
tial ﬁbrosis. This eﬀect may be related to its role in reduc-
ing macrophage accumulation as this study identiﬁed, but
it may also be related to its pleiotrophic eﬀect on other ﬁ-
brogenic factors. As we discussed above, macrophage may
not be the only contributor to interstitial ﬁbrosis, blockade
of the angiotensin II type 2 receptor can also suppress inter-
stitial ﬁbrosis without aﬀecting interstitial macrophage accu-
mulation [28]. As statin holds the capacity of inhibiting an-
giotensin II [13], we guess that atorvastatin can also reduce
ﬁbrosis independent of its role in reducing macrophage ac-
cumulation.
In summary, this study has demonstrated that OPN and
M-CSF expression was upregulated in tubular cells in rat
UUO nephropathy in diﬀerent phases, and correlated with
local macrophage accumulation at related time points. Ator-
vastatinmaydecreasemacrophageaccumulationthroughin-
hibiting OPN and M-CSF expression, and ﬁnally ameliorate
the interstitial ﬁbrosis.
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